(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 0.49% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Viatris's revenue in 2025 is $14,115,700,000.On average, 3 Wall Street analysts forecast VTRS's revenue for 2025 to be $16,164,672,472,711, with the lowest VTRS revenue forecast at $15,993,783,599,824, and the highest VTRS revenue forecast at $16,294,613,584,754. On average, 3 Wall Street analysts forecast VTRS's revenue for 2026 to be $16,461,857,941,372, with the lowest VTRS revenue forecast at $16,297,843,050,546, and the highest VTRS revenue forecast at $16,589,124,542,755.
In 2027, VTRS is forecast to generate $16,685,863,948,365 in revenue, with the lowest revenue forecast at $16,618,807,647,109 and the highest revenue forecast at $16,724,377,368,209.